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http://dx.doi.org/10.1016/j.jacl.2013.03Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein secreted by the hepatocyte
that regulates the surface expression of low-density lipoprotein (LDL) receptors by targeting them for
lysosomal degradation. Statins enhance PCSK9 synthesis, an effect that blunts the LDL-cholesterol
(-C)–lowering effectiveness of statins. Loss-of-function mutations in the PCSK9 gene produce life-
long low levels of LDL-C and reduce cardiovascular risk. Monoclonal antibodies to PCSK9, which
mimic the effects of genetic mutations by inhibiting PCSK9, are in clinical trial development. Two dif-
ferent commercial development programs have demonstrated significant success in lowering LDL-C in
phase 1 and 2 trials with similar agents: REGN727/SAR236553 (REGN727) and, more recently, AMG
145. When administered subcutaneously at doses ranging from 50 to 150 mg every 2 weeks or 200 to
400 mg every 4 weeks, these agents produced similar dose-responses in LDL-C lowering. In hypercho-
lesterolemic patients, LDL-C reductions ranged up to 60%, and, as would be expected, an even greater
response was reported for statin-treated hypercholesterolemic patients—up to 70% decrease. LDL-C
has typically shown a gradual increase after the nadir as monoclonal antibodies are cleared from the
circulation. Results to date indicate that the PCSK9 monoclonal antibody approach appears safe,
well-tolerated, and profoundly lowers LDL-C levels while also favorably altering apolipoprotein B, tri-
glycerides, lipoprotein (a), and high-density lipoprotein-C. It is expected to meet an important clinical
need for patients unable to achieve adequate LDL-C-lowering with currently available therapies.
 2013 National Lipid Association. All rights reserved.Low-density lipoprotein (LDL) is associated with many
genetic mutations or polymorphisms that lead to either
increased or reduced levels of LDL cholesterol (-C).1–4 One
of the polymorphisms leading to low levels of LDL-C is a
mutation in the gene for proprotein convertase subtilisin/
kexin type 9 (PCSK9).5 Loss-of-function mutations in this
gene lead to life-long low levels of LDL-C, which have
been associated with substantial reductions in risk for ische-
mic cardiovascular disease.3,5,6 Clinical trials are underway
to explore a monoclonal antibody approach of targeting
PCSK9 with the intent of markedly reducing LDL-C.7e.bsd.uchicago.edu
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.004Mechanism of action of PCSK9
The hepatic LDL receptor plays a central role in
cholesterol homeostasis.8–10 It is a large, complex protein
with a binding domain for apolipoprotein (Apo) B. This
binding domain is in which most mutations in the LDL re-
ceptor occur. After Apo B (as part of an Apo B–containing
lipoprotein) binds to the LDL receptor, the receptor–Apo B
complex is internalized in a clathrin-coated pit and enters
the hepatocyte.8,10,11 Clathrin then dissociates from the
LDL receptor, and the Apo B particle undergoes lysosomal
degradation, releasing cholesterol. The LDL receptor is re-
cycled back to the surface of the hepatocyte, where it can
again bind with Apo B particles, enabling efficient clear-
ance of LDL from the circulation. PCSK9 is a proteins reserved.
S12 Journal of Clinical Lipidology, Vol 7, No 3S, June 2013secreted by the hepatocyte that ‘‘chaperones’’ the LDL re-
ceptor from the cell surface, into the coated pit, and into
the cell for degradation and recycling.9,12,13 PCSK9 regu-
lates the surface expression of LDL receptors by targeting
them for lysosomal degradation. Statins, bile acid seques-
trants, and ezetimibe stimulate LDL receptor up-
regulation by decreasing the amount of cholesterol in the
hepatocyte. This is a tightly regulated system; however,
in a counter-regulatory action by the liver, statins also pro-
duce PCSK9 up-regulation.14 Thus, the potential reduction
in LDL-C provided by some LDL-C–lowering drugs is lim-
ited by this compensatory increase in PCSK9.
Gain-of-function and loss-of-function mutations in
PCSK9 have been described.13 Gain-of-function mutations,
which are rare, result in fewer LDL receptors and increased
LDL-C.15 Loss-of-function PCSK9 mutations lead to de-
creased LDL receptor degradation, resulting in more LDL
receptors residing on the surface of the liver and lower
LDL-C concentrations. LDL-C was 15% to 28% lower
and ischemic heart disease incidence was reduced by
47% to 88% in PCSK9 loss-of-function carriers compared
with those lacking such mutations.3 Monoclonal antibody
techniques, similar to those used in other areas of medicine
such as anti-tumor necrosis factor for neutralizing the in-
flammatory effects of tumor necrosis factor in rheumatoid
arthritis and inflammatory bowel disease, have been used
to create products which manipulate PCSK9 levels. In the
case of PCSK9, a monoclonal antibody binds to the
PCSK9 protein, thereby inhibiting its effect on the LDL re-
ceptor (Fig. 1).16
Monoclonal antibody to PCSK9
Several monoclonal antibodies to PCSK9 are in clinical
trial development. This article is a summary of aFigure 1 Mechanism of PCSK9 inhibition with monoclonal anpresentation on PCSK9 inhibition that was given at the
2012 National Lipid Association Annual Scientific Ses-
sions. At that time, most of the published data came from
studies of REGN727/SAR236553 (REGN727; Regeneron
Pharmaceuticals, Inc. [Tarrytown, NY] and Sanofi-Aventis
[Reston, VA]) and were thus emphasized in the presenta-
tion. More recently, data from phase 1 and 2 trials of AMG
145 (Amgen, Washington, DC), another fully human mon-
oclonal antibody to PCSK9, have been published and are
described briefly in this report, although they were not part
of the original presentation.
In the first set of phase 1 studies of a PCSK9 monoclonal
antibody in humans, a group of healthy volunteers were
administered single-dose intravenous or subcutaneous
REGN727 injections (intravenous results are not shown
here) and another group of patients with heterozygous
familial hypercholesterolemia and nonfamilial hypercho-
lesterolemia, who were following a modified diet, were
administered multiple subcutaneous REGN727 injections
on days 1, 29, and 43.17 In these studies the administration
of REGN727 led to profound effects on LDL-C concentra-
tion. Notably, a single dose in healthy volunteers led to
50%-70% reductions in LDL-C (Fig. 2).17
In a 12-week placebo-controlled study in which
REGN727 was injected every 2 weeks (Q2W) or Q4W
in patients with primary hypercholesterolemia, McKenney
et al18 showed a 30.5% LDL-C reduction 2 weeks after
the initial 50-mg Q2W dose that decreased further to a
39.6% change from baseline at 12 weeks (Fig. 3). LDL-C
levels after 12 weeks of 100- and 150-mg Q2W doses
and 200- and 300-mg Q4W doses decreased by 64.2%,
72.4%, 43.2%, and 47.7%, respectively. These were the
mean responses over time; however, the observed pattern
was that upon injection of the PCSK9 monoclonal antibody
there was a large decrease in LDL-C levels followed by atibodies. Reprinted with permission from Lambert et al.16
Figure 2 Percent changes in LDL-C after increasing single doses of monoclonal antibody for PCSK9 (SAR236553/REGN 727) among
healthy volunteers. Reprinted with permission from Stein et al.17
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from the circulation. In addition to reductions in LDL-C,
triglycerides decreased slightly (28.4% with 300 mg),
high-density lipoprotein-C increased (8.5% with 300 mg),
and Apo A1 levels increased at the greatest dose (4.2%
with 300 mg). The incidence of treatment-emergent ad-
verse events was 45% in the group receiving placebo,
60% in the 50-mg Q2W, 65% in the 100-mg Q2W, 61%
in the 150-mg Q2W, 67% in the 200-mg Q4W, and 47%
in the 300-mg Q4W dosing groups.18 There were no in-
stances of elevated liver enzymes (alanine or aspartate ami-
notransferase) greater than 3 times the upper limit of
normal (.3! ULN) or creatine kinase .10! ULN asso-
ciated with administration of the PCSK9 antibody; ,1% of
subjects reported muscle pain or weakness. Injection-siteFigure 3 Percent changes frombaseline inLDL-C after 50-, 100-,
150-, 200-, and 300-mg doses of PCSK9 monoclonal antibody
(SAR236553/REGN727) every 2 weeks for 12 weeks in patients
with primary hypercholesterolemia. Reprinted with permission
from McKenney et al.18reactions occurred in the PCSK9 antibody groups but
were generally mild and nonprogressive.
A placebo-controlled statin combination study investi-
gated the effects of 150 mg of REGN727 Q2W for 8
weeks plus 80 mg/d atorvastatin or a maintenance dose of
10 mg/d atorvastatin (Fig. 4).19 In the group receiving
atorvastatin 80 mg/d plus placebo, there was a decrease
in LDL-C of 17.3% compared with a 73.2% reduction
in LDL-C in the group receiving atorvastatin 80 mg/d
plus REGN727. With the REGN727 plus atorvastatin 10
mg/d combination, LDL-C was decreased by 66.2%. In
addition to its effectiveness for lowering LDL-C, treat-
ment with REGN727 also significantly lowered Apo B,
non–high-density lipoprotein-C, lipoprotein (a), and tri-
glycerides. The mechanism accounting for the 30%-40%
reduction in lipoprotein (a) is not clearly understood.
Safety and tolerability results for the combination of ator-
vastatin plus REGN727 were also favorable.19 Few pa-
tients had elevated liver enzymes (one each with
aspartate aminotransferase elevation .3! ULN, alkalineFigure 4 Percent changes from baseline in LDL-C after 150 mg
PCSK9 monoclonal antibody (SAR236553/REGN727) plus ator-
vastatin 10 or 80 mg/d for 8 weeks in patients with primary hyper-
cholesterolemia. Reprinted with permission from Roth et al.19
S14 Journal of Clinical Lipidology, Vol 7, No 3S, June 2013phosphatase .1.5! ULN, and total bilirubin
.1.5! ULN), none had significantly increased creatine
kinase, and there was just one report of a serious
treatment-emergent adverse event. Injection site skin re-
actions were also rare and mild.
Results from phase 1 and 2 trials of AMG 145 also
demonstrate the safety and efficacy of this PCSK9 inhib-
itor.20–24 In a phase 2 trial reported by Koren et al23 of 406
patients with hypercholesterolemia not receiving concur-
rent lipid-lowering treatment, AMG 145 administered
subcutaneously for 12 weeks at 70, 105, or 140 mg Q2W
or 280, 350, or 420 mg Q4W significantly reduced LDL-
C byw40%-50% in all dose groups (P , .001 for all doses
vs. placebo or vs. 10 mg/d ezetimibe). Treatment-emergent
adverse events occurred in 50% of patients in the AMG 145
groups compared with 46% of those in the placebo group
and 58% receiving ezetimibe. In a large dose-ranging
phase 2 trial of 631 men and women with hypercholesterol-
emia who were receiving statins (with and without ezeti-
mibe), AMG 145 administered at 70, 105, or 140 mg
Q2W for 12 weeks reduced LDL-C by 42 to 66%
(P , .0001 for each dose vs. placebo) and AMG 145 at
280, 350, and 420 mg Q4W for 12 weeks resulted in
LDL-C reductions ranging from 42 to 50% (P , .0001
for each dose vs. placebo; Fig. 5).24 The frequencies of
treatment-related adverse events with AMG 145 andFigure 5 Percent changes from baseline in LDL-C following PCSK9
every 4 weeks in combination with a statin for 12 weeks in patients with
et al.24placebo were similar (8% and 7%, respectively), and
none were severe or life-threatening.Conclusion and future perspectives
In summary, these results demonstrated that a mono-
clonal antibody to PCSK9 was capable of lowering LDL-C
by up to 70% above the level achieved by statin therapy.
There are at least 3 monoclonal antibodies that inhibit
PCSK9 activity as well as an antisense approach in human
trials.25,26 The monoclonal antibody approach is expected
to meet an important clinical need for LDL-C lowering
in patients with statin intolerance, those who cannot
achieve an adequate LDL-C level with existing therapy, re-
fractory hypercholesterolemia, and those who may other-
wise require LDL apheresis. Clinical outcome trials of
PCSK9 monoclonal antibodies are highly anticipated. A
drug such as this, which has the potential of producing
LDL-C levels as low as 25 mg/dL, would be expected to
be associated with a dramatic reduction in cardiovascular
risk. There are a multitude of other genes affecting lipid
metabolism,27 and investigating the effects of additional
genetic variants could potentially lead to the development
of more novel therapeutic targets for managing
dyslipidemia.monoclonal antibody (AMG 145) administered every 2 weeks or
hypercholesterolemia. Reprinted with permission from Giugliano
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